Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+16%
CX
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
+16%
ACAD
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
+15%
PVG
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
+12%
OCLR
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
+12%
ACET
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
+12%
COW
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
+11%
PLKI
Alert Price: $70.82
High Price: $79
Results: 11% in 5 Days
+10%
HWKN
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
+9%
LLY
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

biotech

Top Catalysts For The Week Ending February 24 2017


Exact Sciences = Roth Capital raised to Buy from Neutral and set a price target of $26

Applied Optoelectronics = Announced the immediate availability of 100G QSFP28 10km transceivers based on the 4WDM-10 MSA specification

Mobileye = RBC reiterates an Outperform rating and sets a price target of $57

Bellicum Pharmaceuticals = Positive updates on clinical BP-004 study

Raytheon = gets AED1.29 billion defense deal with UAE Armed Forces

pp250x250

Trading Lessons

Mainstream Financial News

Archives

Orexigen Therapeutics Sell For 157% Win!

February 16, 2017: Sell Orexigen Therapeutics for a 157% win in 36 days! Congratulations if you were able to make money on this trade.

January 25, 2017: Orexigen Therapeutics announced that Laboratorios Farmaceuticos Rovi has launched Mysimba in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult (Read More….)

Sarepta Therapeutics Candle Over Candle On Feuerstein

February 14, 2017: Sarepta Therapeutic’s stock has formed a candle over candle reversal after Feuerstein said, “Sarepta Therapeutics is being dragged down unfairly into the price-gouging muck by Marathon Pharmaceuticals.” Source: https://www.thestreet.com/story/14001431/1/defending

January 10, 2017: Baird reiterates a Buy rating on biotechnology firm Sarepta Therapeutics and set a price target of $102. Baird named Sarepta (Read More….)

Actinium Pharmaceuticals Basing Off Of Double Bottom

February 7, 2017: Actinium Pharmaceuticals announced today that a Phase 1 clinical trial studying Actimab-M in multiple myeloma has been initiated. Actimab-M is comprised of the CD-33 targeting monoclonal antibody HuM-195 coupled to the alpha-particle emitter actinium 225. CD33 is an antigen found on hematopoietic cells in certain blood cancers. It is commonly associated with (Read More….)

Sell Teva Pharmaceutical For -1.54% Loss On California Lawsuit

February 5, 2017: Sell Teva Pharmaceutical for a -1.54% loss. Sorry folks but better to get out for a small loss as not sure how big of penalties we’re looking at IF Teva is found guilty of actually doing what the State of California is saying they did but I’m thinking possibly hundreds of millions. (Read More….)

Ocera Therapeutics Sell For 77% Loss

January 31, 2017: Sell Ocera Therapeutics for a -77% loss. OCRX’s long-awaited Phase 2 program disappointed as IV OCR-002 missed the primary endpoint. This stock did not pass my quality control (rising earnings and revenue) when I began tracking it but there was lots of buzz around IV OCR-002 results coming at the end of (Read More….)

Ironwood Pharmaceuticals Reports Positive Top-Line Results from Phase III Linaclotide Trial

January 29, 2017: Astellas Pharma and Ironwood Pharmaceuticals announced today top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults with chronic constipation (CC) met its primary endpoint.

Linaclotide is approved in Japan as the first prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C). Linaclotide is (Read More….)

Top Performing Stocks On GuerillaStockTrading For Week Ending January 27 2017

OREX continues to be our dominant stock pick up a whopping +80% since profiled on GuerillaStockTrading.com

The biggest new gainer this last week was PLX which rocketed higher after it received FDA Orphan Drug Designation for CTP-656 for the treatment of Cystic Fibrosis.

Another big climber was CGIX after it launched its entry into comprehensive (Read More….)

TheStreet.com’s Feuerstein Says Celgene Should Buy Biogen

January 23, 2017: TheStreet.com’s Feuerstein says Celgene should considering buying Biogen. Source: http://realmoney.thestreet.com/articles/01/23/2017/5-reasons-celgene-should-buy-biogen

January 13, 2017: Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy (SMA) compared to untreated infants. (Read More….)

AbbVie Gets FDA Approval For Imbruvica

January 19, 2017: AbbVie announced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This indication is approved under accelerated approval based on overall response rate (ORR), and (Read More….)

Jazz Pharmaceuticals Leerink Reiterates Outperform Rating, Price Target $182

January 18, 2017: Leerink reiterates their Outperform rating on Jazz Pharmaceuticals and sets a price target of $182 after yesterday evenings FDA updates regarding a generic Xyrem (naracolepsy) application appear to be a net-positive for JAZZ as the FDA concurrently ruled (in a citizens petition [CP]) that it won’t allow generic substitutes to carve-out safety/dosing (Read More….)

Avondale Partners Raised McKesson To Market Outperform

January 17, 2017: Avondale Partners raised McKesson to Market Outperform from Market Perform.

January 17, 2017: McKesson agrees to $150 million settlement with DOJ over failure to report suspicious orders of drugs. The nationwide settlement requires McKesson to suspend sales of controlled substances from distribution centers in Colorado, Ohio, Michigan and Florida for multiple years. (Read More….)

Horizon Pharma Guides On Track To Deliver $2 Billion In Sales by 2020

January 10, 2017: In a JPM slide presentation, Horizon Pharma says it’s on track to deliver $2 billion in total net sales by 2020.

December 22, 2016: Horizon Pharma announces that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 13/610,580, entitled “Methods of (Read More….)

Novo Nordisk Marketing Authorization Granted by European Commission For Fiasp

January 10, 2017: Novo Nordisk A/S B announces marketing authorization granted by European Commission for Fiasp for treatment of diabetes in adults. Novo Nordisk expects to launch Fiasp in the first European countries in the first half of 2017. The authorisation covers all 28 European Union member states.

Fiasp is the brand name for fast-acting (Read More….)

ARIAD Pharmaceuticals Sell For 86.7% Win!

January 9, 2017: Sell ARIAD Pharmaceuticals on the news that it will be acquired by Takeda for $24 per share. This was a monster 86.7% win for us. Congratulations if you were able to make money on the trade.

January 4, 2017: Seeing heavy weekly call activity in Ariad Pharmaceuticals: 1,684 Jan 13 $13 (Read More….)

BTIG Initiates Coverage of Nektar Therapeutics With a Buy Rating, Price Target $22

January 8, 2017: BTIG initiates coverage of biotechnology firm Nektar Therapeutics with a Buy rating, and a price target of $22. Nektar Therapeutics stock chart has just done a breakout above $13.50 resistance.

Nektar Therapeutics Stock Chart

Nektar Therapeutics is a clinical-stage biopharmaceutical company with a proven track record of discovering and (Read More….)

Anavex Life Sciences Institutional Traders Accumulating

January 8, 2017: Institutional traders are accumulating biotechnology firm Anavex Life Sciences according to recent 13F filings. The institutional traders who bought the most shares of Anavex Life Sciences are:

BlackRock Fund Advisors = bought 843,994 shares according to 11-11-2016 filing BlackRock Institutional Trust = bought 284,540 shares according to 11-11-2016 filing State Street Corp (Read More….)

Halozyme Therapeutics Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints

January 6, 2017: Halozyme Therapeutics reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO 202 study, a Phase 2 randomized, multi-center clinical trial of lead investigational drug PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine in stage IV pancreas cancer patients.

Among the findings, the (Read More….)

Depomed Inc Said To Have Received One Bid

January 6, 2017: Depomed Inc said to have received one bid according to reports in the mainstream financial media. Recent mainstream media commentary on potential sale of Depomed:

– On Dec 31st KKR remains interested in acquiring Depomed – NY Post

– One analyst cited expects a deal would value DEPO at $25/shr or $1.5 (Read More….)

Teligent Gets FDA Approval For Three ANDAs

January 03, 2017: Biotechnology firm Teligent announced it has received approval of three of the Company’s abbreviated new drug applications (ANDAs) from the U.S. Food and Drug Administration (FDA) of Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram and 1 mg/gram, Clindamycin Phosphate Topical Solution USP, 1% and Flurandrenolide Ointment USP, 0.05%. These approvals were (Read More….)

Eli Lilly Sell For 8.8% Win In 12 Days

December 29, 2016: Sell Eli Lilly for an 8.8% gain in 12 trading days. Congratulations if you were able to make money on the trade.

December 16, 2016: Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with Type 1 diabetes. This is a successful completion of an (Read More….)

Recro Pharmaceuticals Sell For 19.7% Win In 11 Days

December 29, 2016: Sell Recro Pharmaceuticals for a 19.74% win in 11 trading days. Congratulations if you were able to make money on the trade.

December 19, 2016: Piper Jaffray/Simmons initiates coverage of Recro Pharmaceuticals with an Overweight rating, and sets a price target of $12.

December 14, 2016: Broadfin Capital discloses amended 16.43% stake (Read More….)

Conatus Pharmaceuticals Sell For 23% Gain In 3 Days

December 29, 2016: Sell Conatus Pharmaceuticals for a monster 23.02% gain in just 3 trading days. Congratulations if you were able to make money on the trade.

December 26, 2016: Biotechnology firm Conatus Pharmaceuticals gets a price target upgrade after news of deal with Novartis. JMP Securities raised the price target for Conatus Pharmaceuticals to (Read More….)

Tonix Pharmaceuticals J Hook Bottom On Breakthrough Therapy Designation

December 28, 2016: Tonix Pharmaceuticals is forming a wide J Hook pattern after having the FDA granted their PTSD drug TNX-102 a Breakthrough Therapy designation.

December 19, 2016: Tonix Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to TNX-102 SL for the treatment of posttraumatic stress disorder (Read More….)